Nootropics Index - Save on smarter supplements
Synthetic nootropics & research compounds

Cardarine

GW501516 (Cardarine)

Cardarine (GW501516/GW1516) is an investigational PPAR-delta agonist often sold beside SARMs. Short human studies measured blood lipids, not cognition or athletic performance. Official warnings flag serious animal toxicity; consumer dosing safety is unestablished. Compare listing units and evidence carefully, and note that the 2026 WADA list prohibits it at all times in covered sport.

Isolated CompoundSyntheticClinical ResearchLimited Human EvidenceInsufficient EvidencePopulation Specific EvidenceHigh Risk Profile
Updated October 2026/6 min read/10 citations
Reviewed by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
Extra caution

Who should avoid this or get expert review first

This is not a recommendation to use. These groups should treat the profile as a reason to slow down and verify safety, rules, and personal context.

  • Athletes subject to WADA rules3GW1516/GW501516 is listed under S4.4.1 metabolic modulators in the 2026 WADA list. It is prohibited at all times, including outside competition.
01

What is it?

What is Cardarine?

1

GW501516, also called GW1516, Cardarine or Endurobol, is a synthetic small molecule that activates PPAR-delta, a receptor involved in lipid metabolism. Its mechanism differs from selective androgen receptor modulators (SARMs), despite appearing beside them in online catalogs.

Investigational compound with a safety warning2
WADA reported that development ended after serious animal toxicology findings. Health warnings apply to the compound itself; a retailer listing is not evidence of an approved or safe human-use product.
02

Names, aliases and forms

Common NameCardarine
Research CodesGW501516; GW-501516; GW1516; GW-1516; GSK-516
Trade NameEndurobol
Cas Number317318-70-0
Pubchem Cid9803963
Molecular FormulaC21H18F3NO3S2
InchikeyYDBLKRPLXZNVNB-UHFFFAOYSA-N
03

Potential effects and evidence map

Small and short human trials report changes in lipid biomarkers. Those findings are indirect for memory, focus, fat loss or endurance, and do not establish long-term consumer safety. The overall grade applies to marketed nootropic and performance uses, not to whether lipid pharmacology was observed.

Effect domainMagnitudeGrade
Physical energy / endurance7
UnknownConfidence: Low

Human lipid trials do not establish an endurance or exercise-performance benefit.

Note Zero denotes insufficient relevant human evidence, not proof that the compound is inactive.

0/5
E
Mental energy / wakefulness5
UnknownConfidence: Low

The cited human research does not demonstrate a mental-energy or alertness benefit.

Note Blood-lipid outcomes cannot serve as cognitive-performance outcomes.

0/5
E
Memory / learning6
UnknownConfidence: Low

Memory and learning benefits are unestablished by the available human lipid studies.

Note No relevant memory endpoint is reported in these trials.

0/5
E
04

Typical dosages and timing

Research context only72.5, 5 or 10 mg/day

Adults with low HDL received one of these doses or placebo in the published study. These are historical investigational exposures, not a supplement dose recommendation; no validated safe consumer regimen follows from this trial.

05

Timing & effect horizon

Effect horizonUnknown
Unknown
Study window7Cumulative
12 weeks
Study length is not an effect duration8

The featured study window describes repeated dosing in a lipid trial. It does not show when a cognitive or endurance effect starts, how long one dose acts, or an appropriate cycle. Hair-detection research likewise cannot supply an effect-duration or safe washout value.

06

Safety, side effects and risk profile

Animal cancer findings and the limits of human data9
Health Canada reports that development stopped following toxicities, including multiple cancers, in long-term animal studies. Human cancer incidence at retail-use doses is unknown. The concern is potentially severe; its human probability and reversibility after stopping are unestablished. Feeling well during a short exposure cannot settle a long-term hazard.
Pregnancy, breastfeeding and children10
Adult lipid studies cannot establish safety in pregnancy, breastfeeding or children. The TGA assessment also identifies reproductive toxicity findings in animals; it does not provide a safe exposure threshold for these groups.
Legal / regulatory risk3
Confidence: High

For athletes under WADA rules, GW501516 is prohibited in and out of competition in 2026.

Note This is a directly documented sporting rule, not human efficacy evidence. U.S. product-market status is discussed separately; legal status does not determine intrinsic base risk.

4/5
E
Evidence uncertainty9
Confidence: High

Official warnings cite serious animal toxicity, including cancers; long-term risk in humans cannot be quantified.

Note High concern is anchored to the intrinsic hazard described by authorities, including oral-use contexts. Moderate would understate the severity prompting abandoned development and consumer warnings. Human studies lasting at most 12 weeks cannot resolve cancer risk; likelihood at those doses and reversibility after stopping are unknown. Critical is not selected because severe human harm at ordinary research exposures is not established. Product quality, sports eligibility and special populations are separate cautions.

4/5
D
07

Interactions and cautions

Interactions and stacks are not established10

The short lipid-study record does not define safe combinations with medicines, SARMs or other performance products. Lack of established interaction data is not evidence that combining them is safe; specific CYP or organ-interaction claims are not supported here.

09

How it compares

Human evidence versus performance marketing7

A 12-week placebo-controlled trial in 268 adults with low HDL measured lipids and apolipoproteins. It reported biomarker changes, including an HDL increase of up to 16.9% at the highest dose. That is not a demonstrated improvement in memory, running performance, body-fat loss or cardiovascular events.

10

Practical buying and quality notes

  • For a label stating 60 capsules at 10 mg each, the declared pack total is 600 mg. Per-capsule and per-pack prices answer different questions; compare matching quantities and strengths. This is label arithmetic, not verification of contents, consumer safety or an endorsement. A research-use disclaimer does not establish approval for human use. An offer row's labeled amount may represent a pack total rather than each capsule. Verify the amount basis on the merchant page; a pack total is not a single-dose amount.4
11

FAQ

Do human studies support Cardarine as a nootropic?

6

The studies cited here examined lipid metabolism rather than memory or attention. Their results do not establish a cognitive benefit.

Is Cardarine a SARM?

1

Its target is PPAR-delta, not the androgen receptor. Shared retail categories do not make these compounds pharmacologically interchangeable.

Does short-term human tolerability establish safety?

10

The TGA assessment reports no significant adverse effects in the short human studies it reviewed. That observation does not answer the animal cancer concern or establish long-term human safety.

Does research-use-only labeling mean safe for people?

4

No. Research labeling does not establish safety, approval or permission for human use. FDA evaluated the named products by their intended use, including website claims, despite such disclaimers.

12

References

  1. PubChem. Compound Summary for CID 9803963, GW501516.
  2. World Anti-Doping Agency. WADA issues alert on GW501516.
  3. World Anti-Doping Agency. The 2026 Prohibited List.
  4. U.S. Food and Drug Administration. Dynamic Health Group dba SARMS AMERICA - Warning Letter 719257. December 12, 2025.
  5. Sprecher DL et al. Triglyceride:high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor delta agonist. Arterioscler Thromb Vasc Biol. 2007;27(2):359-365.
  6. Ooi EMM et al. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity. J Clin Endocrinol Metab. 2011;96(10):E1568-E1576.
  7. Olson EJ et al. Lipid effects of peroxisome proliferator-activated receptor-delta agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome. Arterioscler Thromb Vasc Biol. 2012;32(9):2289-2294.
  8. Testing for GW501516 (cardarine) in human hair using LC/MS-MS and confirmation by LC/HRMS. Drug Test Anal. 2020.
  9. Health Canada. Unauthorized products may pose serious health risks (February 10, 2020 to March 13, 2020).
  10. Therapeutic Goods Administration. Scheduling delegates' interim decisions and invitation for further comment: ACCS/ACMS, November 2017. Published 5 February 2018; Cardarine assessment, pages 19-30.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.